10-Q/A

                                    AMENDMENT
                                       TO
                                    FORM 10-Q
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

(MARK ONE)

             [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                For the quarterly period ended January 31, 1997

                                       OR

          [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

For the transition period from                 to    
                              -----------------  -----------------
Commission file number 0-5958
                       ------

                       MERIDIAN MEDICAL TECHNOLOGIES, INC.
                       -----------------------------------
             (Exact name of Registrant as specified in its charter)

              DELAWARE                                   52-0898764
 -------------------------------                    ----------------------
 (State or other jurisdiction of                      (I.R.S. Employer
  incorporation or organization)                    Identification Number)


10240 OLD COLUMBIA ROAD, COLUMBIA, MARYLAND                  21046
- -------------------------------------------                 -------
  (Address of principal executive offices)                 (Zip Code)

Registrant's telephone number, including area code:       410-309-6830


Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months, and (2) has been subject to such filing
requirements for the past 90 days. 

                              YES [X]        NO [ ]

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.


                      CLASS OUTSTANDING AT FEBRUARY 28, 1997
                  ---------------------------------------------
                  COMMON STOCK, $.10 PAR VALUE 2,912,502 SHARES





                                          1

THE PURPOSE OF THIS FILING IS TO AMEND THE 2nd QUARTER 10-Q FILED 3/97
BY ATTACHING THE FINANCIAL DATA SCHEDULE EXHIBIT 27



                       MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                    AMENDMENT
                                       TO
                                    FORM 10-Q
                     FOR THE QUARTER ENDED JANUARY 31, 1997


ITEM 6.   EXHIBITS AND REPORTS ON FORM 8-K

     (a)  Exhibits:

          27 Financial Data Schedule

               The following document is filed as part of this report:
                    
                    1) Financial Data Schedule as Exhibit 27
                       contains summary financial information 
                       extracted from the Consolidated Condensed
                       Balance Sheets and Statements of Income and
                       is qualified in its entirety by reference to 
                       such financial statements. 


                                       2



                                   
                       MERIDIAN MEDICAL TECHNOLOGIES, INC.

                                   AMENDMENT
                                       TO
                                    FORM 10-Q

                     FOR THE QUARTER ENDED JANUARY 31, 1997


                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                     MERIDIAN MEDICAL TECHNOLOGIES, INC.
 
- -----------------------------------
                                                 Registrant



   May 27, 1997                      By:  /s/JAMES H. MILLER
- --------------------                      --------------------------
     Date                                 James H. Miller
                                          President and
                                          Chief Executive Officer
                                          (Principal Executive Officer)



   May 27, 1997                      By:  /s/George Troy Braswell
- ---------------------                     ---------------------------
      Date                                George Troy Braswell
                                          Vice President 
                                          and Chief Financial Officer
                                          (Principal Financial and
                                          Accounting Officer)


                                       3

EX-27

 


<ARTICLE>                     5
<LEGEND>
     Consolidated Condensed Balance Sheets and Statement of Income

<MULTIPLIER>                                   1,000
<CURRENCY>                                     U.S. DOLLARS
       
                                     
<PERIOD-TYPE>                           6-MOS
<FISCAL-YEAR-END>                              JUL-31-1997
<PERIOD-START>                                 NOV-01-1996
<PERIOD-END>                                   JAN-31-1997
<EXCHANGE-RATE>                                1.000
<CASH>                                         614,100
<SECURITIES>                                   260,900
<RECEIVABLES>                                  7,233,200
<ALLOWANCES>                                   0
<INVENTORY>                                    5,900,000
<CURRENT-ASSETS>                               15,890,600
<PP&E>                                         27,801,000
<DEPRECIATION>                                 12,808,000
<TOTAL-ASSETS>                                 43,935,000
<CURRENT-LIABILITIES>                          15,019,800
<BONDS>                                        13,504,100
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       291,300
<OTHER-SE>                                     11,683,500
<TOTAL-LIABILITY-AND-EQUITY>                   43,935,000
<SALES>                                        18,983,600
<TOTAL-REVENUES>                               18,983,600
<CGS>                                          11,968,300
<TOTAL-COSTS>                                  21,894,800
<OTHER-EXPENSES>                               (124,300)
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             1,606,400
<INCOME-PRETAX>                                (4,393,300)
<INCOME-TAX>                                   367,000
<INCOME-CONTINUING>                            (265,200)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (5,025,500)
<EPS-PRIMARY>                                  (4.94)
<EPS-DILUTED>                                  (4.94)



<F1>(29)Includes 3,948,600 of write off costs associated with merger
<F2>(25)Includes long-term notes payable of $13,504,100 of assumed debt related
        to merger
<F3>(32)Includes $1,485,600 of interest expense on debt assumed in merger